Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 129

Sort by

Sort Order Select

Journal Articles

A Case of Mistaken Identity: TTP-like State Due to Heroin Overdose

Phani Borra, MD, Cory Edward Mellon, MD

Blood (2019) 134 (Supplement_1): 4905.

https://doi.org/10.1182/blood-2019-128537

Published: 2019

Journal Articles

Total Body Irradiation Free Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide for Children with Sickle Cell Disease

Satya Prakash Yadav, MBBS, DCH, DNB, Anil Sharma, MBBS, MD, Rohit Kapoor, MBBS, MD, Goutomi Chatterjee, MBBS, MD, Dhwanee Thakkar, MBBS, MDFNB, Neha Rastogi, MBBS,DCH,DNB

Blood (2019) 134 (Supplement_1): 5661.

https://doi.org/10.1182/blood-2019-130988

Published: 2019

Journal Articles

A Case Report of the Benefit of Cannabidiol (Cannabidiol (CBD)-Predominant Medical Cannabis Preparation) in the Management of Refractory Skin Graft Vs Host Disease (GVHD)

Tsiporah B. Shore, MD, Jessy B. Ryan, ANP, Michael B. Samuel, MD

Blood (2019) 134 (Supplement_1): 5687.

https://doi.org/10.1182/blood-2019-122715

Published: 2019

Journal Articles

Response to Brentuximab Vedotin and Quality of Life in Patients with Relapsed/Refractory Hodgkin Lymphoma (RR HL) in the Real World Setting

Blood (2019) 134 (Supplement_1): 5296.

https://doi.org/10.1182/blood-2019-121997

Published: 2019

Journal Articles

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predictive Biomarkers and Clinical Outcomes

Noa G. Holtzman, MD, Soren M. Bentzen, PhD DMSc, Vivek Kesari, MD, Ali Bukhari, MD, Firas El Chaer, MD, Elizabeth Hutnick, RN, Kathleen Ruehle, RN, Natalie Gahres, RN, Neil Porter, MD, Carl Shanholtz, MD, Mehmet Hakan Kocoglu, MD, Ashraf Z. Badros, Babak Saboury, MD MPH, Jean A. Yared, MD, Nancy M. Hardy, MD, Aaron P. Rapoport, Saurabh Dahiya, MD

Blood (2019) 134 (Supplement_1): 3239.

https://doi.org/10.1182/blood-2019-125400

Published: 2019

Journal Articles

Analysis of the Eligibility of Patients with Sickle Cell Disease for Palliative Care

Pedro de Oliveira Toro da Silva, Cristina Bueno Terzi, MD PhD, Antonio Luis Eiras Falcão, MD PhD, Sara T Olalla Saad, PhD, Fernando Ferreira Costa, MD PhD, Paula De Melo Campos, MD

Blood (2019) 134 (Supplement_1): 4681.

https://doi.org/10.1182/blood-2019-128884

Published: 2019

Journal Articles

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Blood (2019) 134 (Supplement_1): 762.

https://doi.org/10.1182/blood-2019-122451

Published: 2019

Journal Articles

Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel

Ajeet Gajra, MD FACP, Marjorie E Zettler, PhD MPH, Eli G Phillips Jr., PharmD, JD, Andrew J Klink, PhD MPH, Jonathan K. Kish, PhD MPH, Sonam Mehta, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 1952.

https://doi.org/10.1182/blood-2019-129593

Published: 2019

Journal Articles

Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Thomas Alexander, MD MPH, Norman J. Lacayo, MD, Vinod A. Pullarkat, MD, Elias J. Jabbour, MD, Seong Lin Khaw, MD, Charles G. Mullighan, MBBS, MD, Ashish Bajel, MBBS, FRACP, FRCPA, Jessica Leonard, MD, Robin Norris, MD, Jeffrey Rubnitz, MD PhD, Susan I. Vear, MD MSCI, Michelle Schmidt, Bo Tong, PhD, Ying Zhou, PhD, Jeremy A. Ross, PhD, Lindsey Rosenwinkel, Amanda Jacobson, PhD, Su Young Kim, MD PhD, Wendy Stock, MD

Blood (2018) 132 (Supplement 1): 3966.

https://doi.org/10.1182/blood-2018-99-113464

Published: 2018

Journal Articles

Longitudinal Sensitivity of the MD Anderson Symptom Inventory for Acute Myeloid Leukemia

Loretta A. Williams, PhD MSN, BSN, BA, Ting Yu Chen, PhD, Dimitrios P. Kontoyiannis, MD, Jessica R. Galloway-Pena, PhD, Pranoti Sahasrabhojane, MS, Samuel A. Shelburne, MD PhD, Tamara E. Lacourt, PhD, Cobi J. Heijnen, PhD, Qiuling Shi, PhD

Blood (2018) 132 (Supplement 1): 4825.

https://doi.org/10.1182/blood-2018-99-113167

Published: 2018

Journal Articles

Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma

Noa Biran, MD, Shijia Zhang, MD PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD, Michele L. Donato, MD, Alan P Skarbnik, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, David S Siegel, MD PhD

Blood (2018) 132 (Supplement 1): 2154.

https://doi.org/10.1182/blood-2018-99-114832

Published: 2018

Journal Articles

Tolerability and Efficacy of Post Transplant Lenalidomide Maintenance Therapy in Multiple Myeloma: A Real World Single Centre Experience

Chloe Yang, MD BS, Haiyan Jiang, PhD, Esther Masih-Khan, PhD, Christine I Chen, MD FRCP(C), Anca Prica, MD FRCP(C), Donna Reece, MD FRCP(C), Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD FRCP(C), Vishal Kukreti, MD FRCP(C)

Blood (2017) 130 (Supplement 1): 3462.

https://doi.org/10.1182/blood.V130.Suppl_1.3462.3462

Published: 2017

Journal Articles

Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)

Gunjan L. Shah, MD, Andrew Lin, PharmD, Ryan Schofield, MS, Caitlin Sarubbi, AB, Elaina V. Preston, PA-C,MPH, Sean M. Devlin, PhD, Valkal Bhatt, PharmD, Stephen J. Harnicar, PharmD, Elizabeth Hoover, BS, David J. Chung, MDPhD, Parastoo B. Dahi, MD, Guenther Koehne, MDPhD, Roni Tamari, MD, Dean Carlow, MDPhD, Sergio A. Giralt, MD, Heather Landau, MD

Blood (2017) 130 (Supplement 1): 2023.

https://doi.org/10.1182/blood.V130.Suppl_1.2023.2023

Published: 2017

Journal Articles

Symptom Burden of Busulfan and Melphalan Versus Melphalan Alone for Multiple Myeloma

Loretta A. Williams, PhD MSN, BSN, BA, Muzaffar H. Qazilbash, MD, Qiuling Shi, MD PhD, Qaiser Bashir, MD MBBS, Huei K. Lin, MS, Charles S. Cleeland, PhD, Richard E. Champlin, MD

Blood (2017) 130 (Supplement 1): 681.

https://doi.org/10.1182/blood.V130.Suppl_1.681.681

Published: 2017

Journal Articles

a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)

Kami J. Maddocks, MD, Jonathon B. Cohen, MD, Ying Huang, MA, MS, Beth A Christian, MD, Don M Benson, MD PhD, Jeffrey Jones, MD MPH, Christopher Flowers, MD MS, Leonard T. Heffner, MD, Cynthia Jenkins, RN, Jennfer Sexton, MHA, CCRC, Alison Neal, MPH, Melissa Kives, MPH, Kristie A. Blum, MD

Blood (2016) 128 (22): 1776.

https://doi.org/10.1182/blood.V128.22.1776.1776

Published: 2016

Journal Articles

The Prognostic Value for Survival of Patient-Reported Outcomes in Hematological Malignancies: A Systematic Review

Avrita Campinha-Bacote, BS MPH, Peter C Trask, Fabio Efficace, PhD

Blood (2016) 128 (22): 4793.

https://doi.org/10.1182/blood.V128.22.4793.4793

Published: 2016

Journal Articles

Challenges of Assessing Symptom Burden in Patients with Haematological Malignancies

Tatyana Ionova, PhD, Tatyana Nikitina, MD PhD

Blood (2016) 128 (22): 2369.

https://doi.org/10.1182/blood.V128.22.2369.2369

Published: 2016

Journal Articles

Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium

Michael J. Burke, MD, Patrick Brown, MD, Richard Sposto, PhD, Lia Gore, MD, Alan S. Wayne, MD

Blood (2016) 128 (22): 2781.

https://doi.org/10.1182/blood.V128.22.2781.2781

Published: 2016

Journal Articles

A Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (NHL)

Kami J. Maddocks, MD, Jonathon B. Cohen, MD, Beth A Christian, MD, Don M Benson, MD PhD, Kristie A. Blum, MD

Blood (2015) 126 (23): 5114.

https://doi.org/10.1182/blood.V126.23.5114.5114

Published: 2015

Journal Articles

Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Frederick L. Locke, MD, Sattva S. Neelapu, MD, Nancy L Bartlett, MD, Tanya Siddiqi, MD, Julio C. Chavez, MD, Chitra M. Hosing, MD, Armin Ghobadi, MD, Lihua E. Budde, MD PhD, Lynn Navale, MS, Jeff S. Aycock, BA, Jeff Wiezorek, MD MS, William Y. Go, MD PhD

Blood (2015) 126 (23): 3991.

https://doi.org/10.1182/blood.V126.23.3991.3991

Published: 2015

NARROW

A Case of Mistaken Identity: TTP-like State Due to Heroin Overdose

Total Body Irradiation Free Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide for Children with Sickle Cell Disease

A Case Report of the Benefit of Cannabidiol (Cannabidiol (CBD)-Predominant Medical Cannabis Preparation) in the Management of Refractory Skin Graft Vs Host Disease (GVHD)

Response to Brentuximab Vedotin and Quality of Life in Patients with Relapsed/Refractory Hodgkin Lymphoma (RR HL) in the Real World Setting

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predictive Biomarkers and Clinical Outcomes

Analysis of the Eligibility of Patients with Sickle Cell Disease for Palliative Care

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel

Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Longitudinal Sensitivity of the MD Anderson Symptom Inventory for Acute Myeloid Leukemia

Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma

Tolerability and Efficacy of Post Transplant Lenalidomide Maintenance Therapy in Multiple Myeloma: A Real World Single Centre Experience

Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)

Symptom Burden of Busulfan and Melphalan Versus Melphalan Alone for Multiple Myeloma

a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)

The Prognostic Value for Survival of Patient-Reported Outcomes in Hematological Malignancies: A Systematic Review

Challenges of Assessing Symptom Burden in Patients with Haematological Malignancies

Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium

A Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (NHL)

Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only